Search

News Instead of NSAIDs, consider combining paracetamol with a weak opioid

Chronic non-cancer pain is a problem that primary care physicians encounter on a daily basis. In the following interview with general practitioner MUDr. Michaela Wichová, we discuss how to approach a patient who complains of pain, what to remember during examination, and which analgesics are appropriate to start treatment.

Source: Updates in Pain Treatment 1. 11. 2023

News Allergic Rhinitis in the General Practitioner’s Office: How to Proceed in Primary Care?

Up to 60% of the population has a genetic predisposition to allergic disease. Diagnosis and therapy of allergic conditions are therefore very common topics in primary care. How should we proceed correctly in the diagnostic process when suspecting allergic rhinitis? When to refer to a specialist and what are the treatment options?

Source: Life Without Allergic Rhinitis 7. 6. 2022

News EULAR 2023: How does tofacitinib affect cardiovascular risk in rheumatoid arthritis?

At this year's European League Against Rheumatism (EULAR) congress, held at the turn of May and June in Milan, Italy, a study was presented that examined the impact of tofacitinib use on cardiovascular (CV) risk in patients with active rheumatoid arthritis (RA).

Source: Arthritis 23. 8. 2023

News Does SGLT2 Inhibitor Administration Benefit Diabetics with Low Cardiorenal Risk?

There is growing evidence of the cardiorenal protective effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i, also known as gliflozins), which were developed as antihyperglycemic drugs for the treatment of type 2 diabetes. These antidiabetic medications are recommended for patients with heart or renal disease or at high risk of these complications. However, is it worthwhile to consider their use in diabetics as part of long-term primary cardiorenal prevention? Israeli authors sought the answer to this question.

Source: Diabetes 14. 11. 2022

News Laboratory Safety of Dupilumab Treatment in Children with Atopic Dermatitis Aged 6 Months to 6 Years

Previous clinical studies in children aged 6–12 years with moderate-to-severe atopic dermatitis have demonstrated laboratory safety during dupilumab treatment. The randomized study presented below supplements the data for the age group from 6 months to 6 years.

Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation 1. 9. 2023

News Care for Dental Prostheses: What Did Clinical Study Results Reveal?

Dental prostheses are one of the most common solutions for missing teeth, especially in the elderly population. It is estimated that by 2050 up to 2 billion people will be aged 60 or older. Currently, it's not even half that, so it's likely that the number of people with dental prostheses will continue to increase. What do current research findings on dental prosthesis care reveal, and which cleaning methods have been evaluated as truly effective?

Source: Optimal Care of Dentures 4. 5. 2020

News Ketogenic diet in MS patients as an aid to increase microbiota diversity and quantity

A recent study published in the journal Frontiers in Microbiology explores the role of gut microbiota in multiple sclerosis, specifically the changes in its quantity and the potential for influencing microbiota through a ketogenic diet.

Source: Multiple Sclerosis 21. 2. 2020

News Management of Adverse Effects During Maintenance Treatment of AML Patients

The randomized phase III study QUAZAR AML-001 evaluated the maintenance treatment of acute myeloid leukemia (AML) in patients after first remission. The following text summarizes the findings regarding the most common adverse events (AEs) in this therapy and practical recommendations for managing side effects based on guidelines from professional societies.

Source: Acute Myeloid Leukemia 4. 9. 2023

News Rapid Diagnosis of Depression in Primary Care Settings

Depression is one of the most commonly occurring psychiatric disorders encountered in general practitioners' offices. The general public also very often uses the term “depression” to mean “bad mood.” Thus, a rapid diagnostic tool to identify “real depression” certainly deserves our attention.

Source: Depression and Anxiety 17. 3. 2020

News Liposomal Ozonated Oil in the Treatment of Eye Infections

Liposomal ozonated oil is a new ocular antiseptic with antibacterial, anti-inflammatory, and regenerative properties, making it suitable for the prevention and treatment of eye infections and as an adjuvant in wound healing. In June 2022, Spanish authors published a review summarizing findings on the mechanism of action and results of preclinical and clinical studies with ozonated oil in the treatment of eye infections and in the regeneration of the ocular surface. It also highlights the benefits of ozonated oil compared to conventional antiseptics such as povidone-iodine and chlorhexidine.

Source: Treatment of Glaucoma 24. 3. 2023

News Epilepsy with Generalized Tonic-Clonic Seizures in an Adolescent Patient –⁠ A Case Study

This is the story of Anička, a 16-year-old girl who has been treated for epilepsy since she was 14. Her condition is accompanied by generalized tonic-clonic seizures, which may need to be managed acutely with rescue medication, either at home or at school. Instead of the previously used rectally administered diazepam, a new, safer and more comfortable option for rescue medication is now available: buccally administered midazolam. This modality may also help alleviate anxiety and other psychological impacts related to the condition, as illustrated by our case study.

Source: Quick aid for acute convulsive seizures in children and adolescents 21. 5. 2024

News Will up-titration or combination with bisoprolol help to better control hypertension in amlodipine users?

Will patients with hypertension who do not achieve control of this condition with amlodipine at a dose of 5 mg benefit more from up-titration or combining it with bisoprolol? The answer to this question was sought in a study published this year by German authors.

Source: Cardiovascular Continuum 25. 10. 2022

News Pharmacological Profile of Mavacamten and Key Studies of Its Use in HCM Treatment

A new addition to the treatment options for hypertrophic cardiomyopathy, approved for use in European Union countries in June 2023, is the selective reversible cardiac myosin inhibitor mavacamten. The following review summarizes its fundamental pharmacological characteristics along with the results of several crucial clinical studies and highlights the potential integration of mavacamten into clinical practice.

Source: Hypertrophic Cardiomyopathy (HCM) 1. 11. 2023

Články časopisu Immunotherapy in the Treatment of Lung Cancer

Author of the article: O. Fiala, O. Šorejs, M. Pešek, J. Fínek Source: Klinická onkologie | Supplementum3/2017 12. 12. 2017

News Critical Conditions in Obstetrics 2022: What is Available in the Czech Republic for Managing Peripartum Life-Threatening Bleeding?

On December 10, 2022, a professional meeting entitled Critical Conditions in Obstetrics 2022 was held in the lecture hall of the new building of the National Museum in Prague. Prof. MUDr. Antonín Pařízek, CSc., from the Department of Gynecology and Obstetrics of the 1st Faculty of Medicine, Charles University, and General University Hospital in Prague, gave a presentation addressing the issue of peripartum life-threatening bleeding (PLTB), the necessities for its management, and provided an overall perspective on the current situation in obstetrics in our country.

Source: Postpartum Hemorrhage 14. 3. 2023